AbbVie’s investigational migraine drug atogepant significantly reduced mean monthly migraine days across a 12-week course of treatment.
Wilmington, Delaware-based Incyte Corporation announced data from the Phase III REACH3 trial of Jakafi (ruxolitinib) in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD).
AbbVie’s Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in a second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.
Eli Lilly’s experimental treatment mirikizumab for plaque psoriasis beat out Novartis’ vaunted drug Cosentyx in a Phase III comparison study.
Evive Biotech announced that the company’s Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients met the primary and secondary endpoints.
Regeneron Pharmaceuticals – with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) – is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
Myovant announced topline results from SPIRIT 1, the second Phase III trial of once-daily relugolix combination therapy in women with pain linked with endometriosis.
Shares of MyoKardia shot up more than 64 percent in trading following an announcement that the company’s lead drug mavacamten hit the mark in a Phase III study of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
Newron Pharmaceuticals, based in Milan, Italy and Morristown, New Jersey, announced topline results from the company’s STARS clinical trial of sarizotan in Rett syndrome. The drug failed to hit the primary or secondary efficacy endpoints.
Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera.